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REVIEW
Abstract: Despite progress in the management of chronic pain, acute pain remains an issue
for many postoperative patients. Although patient-controlled analgesia (PCA) has demonstrated
efficacy and patient satisfaction, current techniques using intravenous (IV) administration
present limitations, including the risk of programming errors and the potential to limit patient
mobility due to pumps, lines, and tubing. The patient-controlled fentanyl hydrochloride (HCl)
iontophoretic transdermal system (fentanyl ITS) was designed to address these concerns.
Fentanyl ITS is an innovative, needle-free, self-contained drug-delivery system that uses
iontophoretic technology to deliver fentanyl through the skin by application of a low-intensity
electrical field. The results of several clinical studies are presented in this review. In three
phase 3 placebo-controlled trials, fentanyl ITS was shown to be superior to placebo for the
treatment of postoperative pain following major abdominal, orthopedic, and thoracic surgery.
The results of one active-comparator phase 3 trial demonstrated comparable safety and efficacy
with a standard morphine IV PCA dosing regimen, without significant difference in the side
effect profile. Fentanyl ITS represents a safe, easy to use, non-invasive, and convenient
alternative to current acute postoperative pain management modalities.
Keywords: patient-controlled analgesia, transdermal, fentanyl, iontophoresis, postoperative
pain, needle-free
Introduction
Despite progress in pain management, moderate-to-severe acute postoperative pain
remains a problem, and has been formally recognized as such by several associations
and societies worldwide, including the Agency for Health Care Policy and Research
(AHCPR; US), the International Association of the Study of Pain, and the Royal
College of Surgeons (UK) (RCSCA 1990; AHCPR 1992; IASP 1992; Stephens et al
2003). According to the AHCPR, the ethical obligation to manage pain and relieve
the patient’s suffering is at the core of a healthcare professional’s commitment, and
anything harmful to the patient, including postoperative pain, should be minimized
or prevented if possible (AHCPR 1992). Acute pain has been associated with
thromboembolic and pulmonary complications, additional time spent in the hospital,
hospital readmission for further pain management, impairment in quality of life, and
the potential to develop chronic pain (ASA et al 2004). Acute pain not only adds
undue physical and emotional stress to the patient, but it can also lead to increased
healthcare costs (Stephens et al 2003)
Patient-controlled analgesia (PCA) refers to a method of pain control that allows
patients to self-administer small doses of an analgesic agent as required. Following
titration to comfort (a score of ≤4 on a scale 0–10; 0 = no pain, 10 = worst possible
pain) using a loading dose of an opioid administered intravenously, PCA allows the
patient to control pain through self-administered, small, intermittent doses of an
analgesic drug as needed (Grass 2005). A study of 200 postsurgical patients
demonstrated a high level of patient satisfaction with PCA, noting that control over
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pain was its most clinically significant feature (top response
by 50.5% of patients) (Chumbley et al 1998). Furthermore,
there is some evidence of a decreased risk of postoperative
pulmonary complications associated with PCA (Walder et
al 2001). Intravenous (IV) PCA using opioids is one of the
most common methods of providing postoperative analgesia
for the treatment of acute pain (Grass 2005). Based on a
meta-analysis of 32 randomized, controlled trials,
intravenous opioid PCA provides better analgesia than
conventional parenteral opioid regimens, without an increase
in opioid-related side effects (Walder et al 2001). While
patient-controlled epidural analgesia (PCEA) offers many
of the same benefits of IV PCA, patient preference study
results indicated that patients prefer IV PCA to PCEA
(Sinatra RS et al 2002).
One of the most common PCA modalities for the
management of acute postoperative pain is morphine sulfate
IV PCA. Although this modality has dramatically improved
postoperative pain management, there are limitations and
potential safety concerns that may restrict its use (Viscusi
and Schechter 2006). Nearly one quarter of the errors that
commonly occur in post-anesthesia care units (PACUs)
involve an improper dose of a medication, and PCA is one
of the problem areas identified (Hicks et al 2004). The most
significant risk when using PCA pumps is accidental
overmedication leading to narcotic-induced respiratory
depression. These pumps require programming by the
clinician, introducing the possibility of complications, or
even death, due to programming errors (Anonymous 1997;
Brown et al 1997; Eade 1997; Vicente et al 2003). Additional
safety issues include possible drug product confusion, device
design flaws, inadequate staff training, prescription errors,
and complications such as IV-related phlebitis (Campbell
1998; ISMP 2003). A recent study of 122 IV drug
preparations found that 4 (3%) had potentially severe errors
in preparation and administration, 38 (31%) had potentially
moderate errors, and 16 (13%) had potentially minor errors
(Taxis and Barber 2004). PCA medical errors can be
dangerous or even fatal (Cohen and Smetzer 2005), and the
risk of errors associated with currently available modalities
may limit their utility.
Furthermore, the IV PCA system requires a pump, line,
tubing, power cables, and pole. These are not only time
consuming to set up and maintain, but may also reduce
patient mobility and interfere with physical therapy (Viscusi
2004). In a recent study (N=77), the unwieldiness of this
set up was one the most frequent reasons for IV PCA
discontinuation (15.6%), second only to stopping treatment
because the patient no longer experienced pain (51.9%)
(Chen et al 2001). Several new technologies offering
alternative routes for PCA administration are being
developed to address the limitations of current PCA
techniques using IV administration.
The patient-controlled fentanyl HCl iontophoretic
transdermal system (fentanyl ITS; IONSYS™, Janssen
Pharmaceutica NV, Beerse, Belgium) (Figure 1) is a needle-
free, self-contained drug-delivery system that uses
iontophoretic technology to deliver fentanyl directly through
the skin by application of a low-intensity electrical field
(Chelly 2005). This review focuses on the technology,
pharmacology, clinical efficacy, and safety of fentanyl ITS.
Fentanyl ITS: technology and
design
Technology
The fentanyl ITS uses non-invasive iontophoretic
technology – based on the electrotransport principle that
similar charges repel each other – to deliver fentanyl through
the skin by application of an external electrical field. A
battery is used to generate a current that flows from the
anode to the cathode, forming a current loop between the
system and the patient. As the anode surface becomes
increasingly positively charged, the similarly positively
charged drug molecules of fentanyl are forced out of the
system across the skin. In addition to fentanyl, this process
has been used for the transdermal delivery of a number of
ionizable drugs such as lidocaine (Bezzant et al 1988;
Galinkin et al 2002; Rose et al 2002; Kearns et al 2003),
morphine (Ashburn et al 1992; Stephen et al 1994), and
corticosteroids (Bertolucci 1982; Nirschl et al 2003).
Although morphine sulfate is the most commonly used
opioid for IV PCA, the properties of fentanyl make it an
optimal candidate for iontophoretic drug delivery. Among
the ideal properties of a drug for transdermal delivery are
low molecular mass and high lipid solubility (Barry 2001).
Compared with morphine sulfate, fentanyl HCl has a lower
molecular weight (372 Da vs 758 Da for morphine sulfate)
and a higher lipophilicity (Peng and Sandler 1999). Fentanyl
is approximately 100 times as potent as morphine (Bovill
1987), enters the central nervous system approximately 133
times as easily, and is metabolized to inactive metabolites
(unlike morphine, which is metabolized to active metabolites
that may be associated with neurotoxicity) (Peng and
Sandler 1999; VHA 2004). Combined with its rapid
induction of analgesia and intermediate duration of actionTherapeutics and Clinical Risk Management 2007:3(1) 21
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(terminal elimination half-life of 2–5 h) (Peng and Sandler
1999), these factors make fentanyl an ideal opioid for acute
postoperative pain management via iontophoresis.
Sufentanil could also be considered for administration via
the transdermal route (Sebel et al 1987).
The optimal dosage of fentanyl for use with iontophoretic
technology was determined based upon results of a
randomized, double-blind, multicenter study conducted to
evaluate the efficacy and safety of 3 doses of fentanyl (20 µg,
40 µg, or 60 µg delivered intravenously at a constant rate
over 10 minutes with a maximum of 6 doses per hour) in
150 patients after major surgery (Camu et al 1998). The
primary efficacy endpoint was assessed by the number of
positive responders, defined as a patient’s global assessment
score of “very good” or “excellent,” plus the absence of
severe adverse effects. Secondary endpoints included pain
Figure 1 The fentanyl hydrochloride iontophoretic transdermal system (fentanyl ITS).
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intensity, the number of valid and invalid demand doses
(invalid demand doses were defined as requests in excess
of the 6 doses/hour limit), and the investigator ratings.
Patients in the 60 µg group had a significantly higher positive
response rate (68%) compared with those of the 20 µg group
(42%; p=0.011). However, there was no significant
difference between the 40 µg group (52%) and the 60 µg or
20 µg groups. The investigator ratings paralleled those of
patients. The number of invalid demands (indicating that
patients were not receiving adequate pain relief [Camu et al
1998]) were significantly higher for the 20 µg group (124
vs 74 [40 µg group] and 85 [60 µg group]; p<0.05). Patients
in the 60 µg group had significantly less pain at rest than
those in the 20 µg and 40 µg groups (p=0.003 and p=0.03,
respectively), and significantly less pain during movement
than those in the 20 µg group (p=0.003). Although the 40 µg
and 60 µg fentanyl doses provided equal analgesia based
on the number of invalid demands, the 60 µg dose was
associated with an increased risk of bradypnea. Taken
together, these data suggest that the 40 µg dose of fentanyl
provided the best combination of efficacy and safety for
fentanyl ITS.
The amount of drug delivered via an iontophoretic
system is correlated with the magnitude of the total electrical
current (Gupta, Bernstein, et al 1998; Gupta, Southam, et al
1998; Gupta et al 1999). To determine the optimal current
for fentanyl ITS, a randomized, open-label study (n=36)
was conducted to investigate several fentanyl ITS prototypes
with different current magnitude/anode area combinations,
including 100 µA/1.38 cm
2, 140 µA/2.72 cm
2, 170 µA/
2.75 cm2, 200 µA/2.75 cm2, and 230 µA/2.75 cm2 (Sathyan,
Jaskowiak, et al 2005). The treatments from each prototype
were administered as 2 consecutive 10-minute doses during
the first 20 minutes of each hour for 23.33 h, with a single
10-minute dose at 23 h. The amount of fentanyl absorbed
from fentanyl ITS was proportional to current for each 10-
minute, on-demand dose and was estimated to be
24.8(±5.2) µg, 35.1(±12.1) µg, 39.5(±10.9) µg,
49.7(±8.8) µg, and 53.9(±12.8) µg for 100 µA/1.38 cm
2,
140 µA/2.72 cm2, 170 µA/2.75 cm2, 200 µA/2.75 cm2, and
230 µA/2.75 cm
2, respectively. Based on these results,
170 µA was considered the optimal current for delivery of
the required 40 µg of fentanyl.
Design
The fentanyl ITS consists of 2 components housed within a
single, compact, self-contained system that may be applied
to the patient’s upper outer arm or chest. The
electromechanical component is located within the top
housing and contains a printed circuit board and integrated
circuit, transducer, capacitors, and lithium battery, as well
as a recessed on-demand button and red light-emitting diode
(LED). The drug component of the system consists of an
anode hydrogel containing fentanyl HCl and a cathode
hydrogel that contains no pharmacologically active
ingredients. An adhesive on the outer edges of the unit allows
the system to be attached to a patient’s skin without the
requirement for venous access. This completely self-
contained, easy-to-use system eliminates the need for the
pump, line, tubing, power cables, and pole associated with
the use of IV PCA.
Based on dose-finding and electrical current studies
(Camu et al 1998; Gupta, Bernstein, et al 1998; Gupta,
Southam, et al 1998; Gupta et al 1999; Sathyan, Jaskowiak,
et al 2005), the fentanyl ITS has been pre-programmed to
deliver fentanyl HCl 40 µg over a 10 min period with each
system, providing a maximum of 6 doses per hour. When
the patient presses the recessed on-demand button twice
within 3 seconds, an electrical current passes through the
fentanyl-containing anode hydrogel. The fentanyl is then
ionized, and the positively charged drug molecules are
repelled from the similarly positively charged anode surface.
A system-initiated lockout prevents the patient from
activating the system for additional drug delivery during
the 10-minute infusion. The system operates for 24 h or
delivers up to 80 doses, whichever occurs first. After this
point, the system is inactivated and unresponsive to
additional requests for medications. Therefore, the system
has to be removed at the conclusion of the 24 h dosing period
and a second system applied if continued analgesia is
required.
A small light-emitting diode (LED) and audible beeps
communicate the system’s dosing status. When the patient
initiates drug delivery by pressing the recessed on-demand
button, an audible beep and a red light from the LED indicate
that a dose has been initiated. After each dose is delivered,
the LED flashes to indicate the cumulative number of doses
a patient has received, with each flash representing up to 5
doses. Healthcare providers may query the system to display
the approximate number of doses delivered at any time.
Each LED flash represents 1–5 total doses administered,
so 2 flashes represent 6–10 doses, 3 flashes represent
11–15 doses, and 16 flashes represent 76–80 doses
administered.Therapeutics and Clinical Risk Management 2007:3(1) 23
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Pharmacokinetics of fentanyl ITS
Dosing frequency
Three randomized, open-label studies were performed to
determine the effect of dosing frequency on the
pharmacokinetics of fentanyl ITS (Sathyan, Zomordi, et al
2005). In the first study, 30 subjects received 3 fentanyl
ITS 25 µg treatments, including 2 sequential doses hourly
for 23.33 h (1A), 6 sequential doses every 3 h for 22 h (1B),
and 72 doses continuously for 12 h (1C). All doses were
delivered on demand over 10 minutes, and the area under
the serum concentration-versus-time curves for a single dose
(AUCn) were calculated by dividing AUC23-24 (for 1A),
AUC21-24 (1B), and AUC” (1C) by the number of doses in
each dosing interval (2, 6, or 72 for 1A, 1B, and 1C,
respectively). The AUCn for 1A and 1B were similar
(0.374 µg · h/L and 0.365 µg · h/L, respectively), suggesting
that the bioavailability of fentanyl is independent of dosing
frequency. Furthermore, the AUCn for 1C, which had a
shorter treatment duration than 1A and 1B, was significantly
lower than 1A or 1B (0.314 µg · h/L; p=0.001), suggesting
that bioavailability increases over time. The second study
paralleled the first study, but investigated a 40 µg dose rather
than a 25 µg dose (Sathyan, Zomordi, et al 2005). The
conclusions of the second study were the same – the
bioavailability of fentanyl delivered via fentanyl ITS
increased as a function of time and was independent of
dosing frequency (Sathyan, Zomordi, et al 2005).
In the third study, 20 subjects received 4 fentanyl ITS
40 µg treatments, including 6 doses over 1 h (3A), 18 doses
over 3 h (3B), 36 doses over 6 h (3C), and 80 doses over
13.33 h (3D) (Sathyan, Zomordi, et al 2005). Based on the
dose-normalized AUC data, 41% of each nominal 40 µg dose
was absorbed into the systemic circulation in the first hour
of treatment, and increased to nearly 100% after 10 h. This
delay in absorption over time is not clinically relevant (since
patients self-administer medication according to their pain
level) and may be due to alterations in the electrical
conduction properties of the skin that may occur as it adjusts
to the current input from fentanyl ITS (Sathyan, Zomordi,
et al 2005).
Multi-day administration and
comparison to fentanyl IV PCA
Another study investigated the effects of single- and
multiple-day administration on the pharmacokinetics of
fentanyl delivered via fentanyl ITS, and compared the
pharmacokinetics of fentanyl ITS versus fentanyl IV PCA
(Sathyan, Jaskowiak, et al 2005). In the administration study,
28 subjects first received a single-day administration of two
10-minute doses of fentanyl 40 µg from the fentanyl ITS
every 4 h for 20 h. This treatment was followed by a multiple-
day administration of two 10-minute doses every 4 h for
68 h, with a new fentanyl ITS placed on a new skin site at
0 h, 24 h, and 48 h. Based on corrected AUC values of
0.40 µg · h/L and 0.54 µg · h/L for the single- and multiple-
day treatments, respectively, there was no significant
difference between study groups (p=0.133), and multiple-
day administration did not alter the pharmacokinetics of
fentanyl ITS (Sathyan, Jaskowiak, et al 2005). The results
of the study comparing the pharmacokinetics of fentanyl
ITS with fentanyl IV PCA (80 µg of IV fentanyl over 20
minutes compared with 2 consecutive 10-minute doses of
40 µg each from the fentanyl ITS) demonstrated that both
modalities display similar pharmacokinetic profiles (Table
1). Additionally, the between-subject variability and decline
in serum fentanyl concentration after completion of
treatment were similar for both fentanyl ITS and fentanyl
IV PCA modalities, suggesting that the use of fentanyl ITS
is not associated with any greater variability in serum
fentanyl concentration than would be seen with fentanyl IV
PCA. After the fentanyl ITS is removed, the decline in serum
fentanyl concentration is similar to IV PCA, suggesting
negligible drug depot in the skin (Sathyan, Jaskowiak, et al
2005).
Effects of application site and subject
demographics
The effects of application site and subject demographics on
pharmacokinetics were also examined (Gupta et al 2005).
The effect of application site was examined in a randomized
Table 1 Pharmacokinetics of fentanyl hydrochloride
iontophoretic transdermal system (ITS) versus fentanyl
intravenous patient-controlled analgesia (IV PCA) (Sathyan,
Jaskowiak, et al 2005)a
Fentanyl Fentanyl
ITS 40 µg IV PCA 80 µg
(n=31) (n=31)
Cmax (µg/L) 1.37 1.82
tmax (h) 0.65 0.58
t1/2 (h) 11.0 12.6
AUC23-24 (µg · h/L) 1.23 1.34
a 80 µg of fentanyl was delivered via IV PCA over 20 min compared with 2
consecutive 10 min doses of 40 µg fentanyl each from the fentanyl ITS.
Abbreviations: AUC, area under serum concentration curve; Cmax, peak serum
concentration; tmax, time to peak serum concentration; t1/2, half-life.Therapeutics and Clinical Risk Management 2007:3(1) 24
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study in which 34 subjects placed fentanyl ITS on the chest,
upper outer arm, or lower inner arm. The results
demonstrated a significantly lower AUC23-24 (AUC for 23–
24 h) with application to the lower inner arm (0.757 µg · h/
L) compared with the upper outer arm (1.033 µg · h/L;
p=0.005) or chest (1.015 µg · h/L; p=0.013). To investigate
the effects of subject demographics on the pharmacokinetics
of fentanyl ITS, 70 subjects received fentanyl ITS 40 µg 3
times during the first 30 minutes of each hour for 3 h and
were evaluated according to age, body weight, gender, and
ethnicity (Gupta et al 2005). The results demonstrated that
none of these demographic characteristics affected the
pharmacokinetics of fentanyl delivered via fentanyl ITS.
Efficacy of fentanyl ITS
The efficacy of fentanyl ITS in treating acute postoperative
pain was first established in three phase 3 double-blind
placebo-controlled clinical trials (Brown et al 1998; Chelly
et al 2004; Viscusi et al 2006). The first of these trials was a
3:1 randomization study in which patients received either
40 µg of fentanyl HCl via fentanyl ITS over 10 minutes
(n=76) or placebo (n=25) for the management of moderate-
to-severe acute postoperative pain (Brown et al 1998).
Patients who received fentanyl ITS had lower dropout rates
(7% vs 38%; p=0.001) (Figure 2) and lower pain intensity
scores on a 100 mm visual analog scale (0 mm = no pain,
100 mm = worst possible pain; 28 vs 37; p=0.016) than
control patients. The fentanyl ITS was also ranked as an
“excellent” method of pain management by significantly
more patients (65% vs 19%; p<0.001) and investigators
(62% vs 19%; p<0.001) compared with placebo.
A second, larger 3:1 randomization study assessed the
efficacy of fentanyl ITS in 189 patients who underwent
major abdominal, orthopedic, or thoracic surgery (Chelly
et al 2004). Patients received a maximum of six 40 µg 10-
minute doses of fentanyl ITS per hour for up to 24 h or 80
doses, whichever occurred first. Fewer patients who received
fentanyl ITS withdrew from the trial because of inadequate
analgesia after at least 3 h of treatment compared with
placebo (25.4 % vs 40.4%; p<0.05) (Figure 2). Patients
treated with fentanyl ITS also reported lower (better) last
pain intensity scores on a 100 mm visual analog scale (0 mm
= no pain, 100 mm = worst possible pain; 30.9 vs 40.8;
p=0.047). The global assessment of method of pain control
was better for fentanyl ITS than placebo based on a 4-point
categorical scale in which 1 = “poor” and 4 = “excellent” as
judged by patients (3.0 vs 2.6; p=0.047) and investigators
(3.1 vs 2.6; p=0.007). One limitation of this study, which
could have minimized the observed efficacy, was that a
greater proportion of patients (5:1) who received fentanyl
ITS had high (≥75 on a 100 mm visual analog scale) baseline
pain intensity scores, even though mean baseline pain scores
between treatment groups were similar. This could have
resulted in higher relative patient withdrawal because of
Figure 2 Withdrawals due to inadequate analgesia in placebo-controlled trials (Brown et al 1998; Chelly et al 2004; Viscusi et al 2006).
Abbreviations: fentanyl ITS, fentanyl hydrochloride iontophoretic transdermal system.
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inadequate analgesia in patients receiving fentanyl ITS
compared with placebo. A third phase 3 study evaluating
the efficacy of fentanyl HCl versus placebo addressed this
limitation by setting a maximum baseline pain score for
enrolled patients (Viscusi et al 2006).
The findings of the largest placebo-controlled trial for
fentanyl ITS were published in 2006 (Viscusi et al 2006).
In this study, 484 patients were treated with fentanyl ITS
(n=244) or placebo (n=240) after major surgery. To
minimize disproportionate baseline pain scores between
groups, only patients with pain scores <5 on an 11-point
scale (0 = no pain, 10 = worst possible pain) were enrolled
following initial IV opioid administration. Half as many
patients treated with fentanyl ITS withdrew from the study
because of inadequate analgesia compared with placebo
(28.7% vs 60%; p<0.0001) (Figure 2), and nearly twice as
many patients were “very satisfied” with their pain
management compared with placebo (61.5% vs 32.1%). The
mean pain intensity scores of fentanyl-treated patients were
significantly lower (better) throughout the 24 h treatment
schedule, including the last pain intensity score on an 11-
point scale (3.5 vs 5.4; p<0.0001). The overall method of
pain control was also described as “excellent” in those who
received fentanyl ITS by significantly more patients (39.8%
vs 14.6%; p<0.0001) and investigators (47.5% vs 20.8%;
p<0.0001) compared with placebo.
In 2004, the results of the first study comparing the
efficacy of fentanyl ITS with morphine IV PCA were
published (Viscusi et al 2004). In this prospective, parallel-
group trial, 636 patients were assigned randomly to receive
IV morphine (1 mg dose as a bolus, with a 5 min lockout
and a maximum of 10 mg/h) by PCA pump (n=320) or
fentanyl ITS (40 µg treatment over 10 min; n=316) (Viscusi
et al 2004). Most patients were female (72.5%), white
(73.7%), and had undergone major abdominal, orthopedic,
or thoracic surgery. Both modalities were therapeutically
equivalent according to pain intensity scores at all assayed
time points during the 24 h treatment period, and the
distribution of patients’ ratings of pain control as poor, fair,
good, or excellent between treatment groups were not
statistically different. Assessment of successful global pain
management was determined by combining patients’ ratings
of pain control as good and excellent for each modality.
These values were similar for fentanyl ITS and morphine
IV PCA (73.7% and 76.9%, respectively; p=0.36) (Figure
3), further suggesting therapeutic equivalence between the
2 PCA systems.
Safety and tolerability of fentanyl
ITS
To date, the safety and tolerability of fentanyl ITS have been
examined in a total of 4 clinical studies (Brown et al 1998;
Chelly et al 2004; Viscusi et al 2004, 2006). Adverse events
associated with fentanyl ITS are similar to those reported
with IV opioid administration, including nausea, vomiting,
pruritus, headache, and mild-to-moderate dizziness. Nausea
was the most common adverse event, with the incidence
ranging between 26.6% and 67.5%. In the active-comparator
phase 3 trial, the incidence of nausea was similar between
fentanyl ITS and IV morphine (Viscusi et al. 2004). Serious
adverse events possibly related to fentanyl ITS included 1
case of severe urinary retention accompanied by moderate
nausea and vomiting (Chelly et al 2004), 2 cases of ileus
diagnosed after removal of fentanyl ITS (Viscusi et al 2006),
and 1 report of severe confusion (Viscusi et al 2004). No
patient treated with fentanyl ITS developed clinical
respiratory depression (defined as the simultaneous
occurrence of bradypnea [respiratory rate <8 breaths per
minute] and excessive sedation) in any of the 4 trials (n=778)
(Brown et al 1998; Chelly et al 2004; Viscusi et al 2004,
2006). Application-site skin reactions, such as erythema,
rash, itching, and vesicles, were also observed in patients
treated with fentanyl ITS, but their incidence was lower than
7% (Brown et al 1998; Chelly et al 2004; Gupta et al 2005;
Viscusi et al 2006). Moreover, most of the application-site
reactions were mild, resembling sunburn or tanning marks,
and none required treatment (Viscusi et al 2006).
Figure 3 Percentage of patients rating pain control as “good” or “excellent” in
the active-controlled trial (Viscusi et al 2004).
Abbreviations: fentanyl ITS, fentanyl hydrochloride iontophoretic transdermal
system; IV, intravenous; PCA, patient-controlled analgesia.
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Conclusions
Findings from several controlled clinical studies indicate
that fentanyl ITS is safe and effective for the management
of acute postoperative pain. The fentanyl ITS allows patients
to maintain an acceptable level of pain control following
titration to comfort with a loading dose of opioid (Viscusi
et al 2004), while avoiding the first-pass effect and analgesic
gaps associated with other pain management modalities.
Patient satisfaction was demonstrated through the low
number of withdrawals due to inadequate analgesia and the
high percentage of patients rating pain control with fentanyl
ITS as good or excellent. Furthermore, fentanyl ITS is the
first needle-free, self-contained, patient-activated system
developed for the management of acute postoperative pain,
making it a safe, easy to use, and convenient modality of
pain relief for both patients and healthcare professionals.
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